Skip to main content

Table 3 Provision of information

From: Medicines information provided by pharmaceutical representatives: a comparative study in Australia and Malaysia

Information   Australia n/58 (%) Malaysia n/125 (%)
Approved product information sheet given Yes 31 (53) 97 (78)
  No 27 (47) 28 (22)
   ^P < 0.001  
Indications Yes 52 (90) 116 (93)
  No 6 (10) 7 (5)
  Unsure 0 2 (2)
   ^*P = 0.33  
Dosage Yes 44 (76) 103 (82)
  No 14 (24) 22 (18)
   ^P = 0.30  
Contraindications Yes 19 (33) 50 (40)
  No 37 (64) 72 (58)
  Unsure 2 (3) 3 (2)
   ^*P = 0.37  
Precautions Yes 21(36) 38 (30)
  No 34 (59) 82 (66)
  Unsure 3 (5) 5 (4)
   ^*P = 0.40  
Drug interactions Yes 19 (33) 31 (25)
  No 38 (65) 89 (71)
  Unsure 1 (2) 5 (4)
   ^*P = 0.30  
Adverse effects Yes 24 (41) 45 (36)
  No 33 (57) 73 (58)
  Unsure 1 (2) 7 (6)
   *P = 0.61  
Did the representative answer your questions on contraindications, precautions, drug interactions, adverse effects? Yes 34/45 (76) 60/105 (57)
  No 2/45 (4) 7/105 (7)
  Partly 9/45 (20) 38/105 (36)
  No question asked 13 20
   ^&P = 0.10  
Given the nature of the drug detailed, do you think the representative should have mentioned contraindications, precautions for use, drug interaction or adverse effects spontaneously? Yes 35 (60) 106 (85)
  No 23 (40) 19 (15)
   ^P < 0.001  
  1. *Chi square test for questions that included variable "unsure" was calculated based on categorical variables "Yes" and "No" only.
  2. &Chi square test for a question with a variable "no question asked" was calculated based on categorical variables "Yes", "No" and "Partly" only.
  3. ^ P-value (Comparison Australia and Malaysia)